GMP IPO
📋 Filings Intelligence
About Contact
LIVE — Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement — financial results, order wins, dividends, mergers and more. Updated live.

—
Filed today
—
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings —

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Morepen Laboratories Ltd

Morepen Laboratories Q2 FY27 Consolidated Net Profit Rises to Rs. 8889.47 Lakhs

RESULTS ▲ Positive Development LOW RISK
📅 Filed on BSE: 27 Oct 2026, 01:36 PM IST  ·  BSE ID: 6e829250-d05d-4390-957d-1a2b01ec4111
View Original BSE Filing (PDF)
💡
In Simple Terms
Morepen Laboratories' Q2 FY27 net profit rose, and a major contingent tax liability was removed by court order.
🤖 AI Summary
  • Consolidated Net Profit after Minority Interest for Q2 FY27 increased to Rs. 8889.47 Lakhs.
  • Revenue from operations (Net) for Q2 FY27 reported at Rs. 74650.19 Lakhs.
  • Contingent liability of Rs. 317.37 crores (inclusive of recovery, interest, and penalty) no longer exists.
  • Board of Directors approved un-audited standalone and consolidated financial results for Q2 and H1 FY27.
  • Final dividend of Rs. 0.20 per equity share for FY26 was paid on October 13, 2026.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Revenue from operations (Net) (Q2 FY27)
Rs. 74650.19 Lakhs
81.39%
Net Profit after Minority Interest (Q2 FY27)
Rs. 8889.47 Lakhs
117.47%
Basic & Diluted EPS (Q2 FY27)
Rs. 1.62
116.00%
Contingent Liability Removed
Rs. 317.37 crores
🏢 How This Affects the Company
📈
Business Impact
The quashing of the show cause notice for Rs. 117.94 crores removes a significant legal challenge, allowing management to focus on core operations. Strong revenue growth in Q2 FY27 indicates expanding market reach or increased product demand.
💰
Financial Impact
Consolidated Net Profit after Minority Interest increased to Rs. 8889.47 Lakhs for Q2 FY27. The removal of the Rs. 317.37 crores contingent liability strengthens the company's financial position by eliminating a potential future outflow.
⚠️
Risk Impact
The successful quashing of the show cause notice by the Hon'ble High Court reduces the company's financial and regulatory risk profile by removing a significant contingent liability.
👥 What This Means For Shareholders
✅
Action Required
No immediate action required by shareholders based on this financial results filing.
👤
Who Is Affected
All shareholders benefit from the strengthened financial position due to the elimination of the Rs. 317.37 crores contingent liability and the increased net profit for Q2 FY27.
🔍
Management Signal
The timely disclosure of financial results and the resolution of the contingent liability indicate proactive financial management and regulatory compliance.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List — track these upcoming events
Q3 FY27 financial results — monitor revenue and profit sustainability.
Future disclosures on contingent liabilities or legal proceedings.
Updates on selling and distribution expenses control measures.
LOW RISK A major contingent liability has been removed, reducing financial risk.
💡 Investor Takeaway
Morepen Laboratories reported consolidated Net Profit after Minority Interest of Rs. 8889.47 Lakhs for Q2 FY27, up 117.47% from Rs. 4087.46 Lakhs in Q2 FY26. Furthermore, a contingent liability of Rs. 317.37 crores was removed due to a favorable court order.
⚖️ Strengths & Concerns

✅ Positives

  • Consolidated Net Profit after Minority Interest for Q2 FY27 surged to Rs. 8889.47 Lakhs, compared to Rs. 4087.46 Lakhs in Q2 FY26.
  • A contingent liability of Rs. 317.37 crores (inclusive of recovery, interest, and penalty) has been eliminated following a favorable court order.

⚠️ Concerns

  • Selling and Distribution Expenses increased significantly to Rs. 7830.16 Lakhs in Q2 FY27 from Rs. 1386.38 Lakhs in Q2 FY26.
  • Cost of Material Consumed increased to Rs. 41190.55 Lakhs in Q2 FY27 from Rs. 22063.31 Lakhs in Q2 FY26, impacting gross margins.
📅 Company Track Record
Morepen Laboratories' Q2 FY27 net profit of Rs. 8889.47 Lakhs builds upon the Q1 FY27 net profit of Rs. 5634.58 Lakhs and Q2 FY26 net profit of Rs. 4087.46 Lakhs, showing a growth trend in reported earnings. The company also declared a final dividend of Rs. 0.20 per equity share for FY26.

Based on publicly available historical data. For context only.

❓ Frequently Asked Questions
What was Morepen Laboratories' consolidated net profit for Q2 FY27?
Morepen Laboratories reported a consolidated Net Profit after Minority Interest of Rs. 8889.47 Lakhs for the quarter ended September 30, 2026 (Q2 FY27).
What was Morepen Laboratories' revenue from operations in Q2 FY27?
Revenue from operations (Net) for Morepen Laboratories in Q2 FY27 stood at Rs. 74650.19 Lakhs.
What was the contingent liability removed for Morepen Laboratories?
A contingent liability of Rs. 317.37 crores (inclusive of recovery amount, interest, and penalty) as of March 31, 2026, was quashed by the Hon'ble High Court of Himachal Pradesh, Shimla.
What was the Basic & Diluted EPS for Morepen Laboratories in Q2 FY27?
The Basic & Diluted EPS for Morepen Laboratories for Q2 FY27 was Rs. 1.62.
What dividend was paid by Morepen Laboratories recently?
Morepen Laboratories paid a final dividend of Rs. 0.20 per equity share of face value Rs. 2.00 each on October 13, 2026.

Questions based on this BSE filing only. For information purposes.

⚠️ For Information Only — Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector — takes 5 seconds.